Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • Office of Undergraduate Research (MU)
    • Undergraduate Research and Creative Achievements Forum (MU)
    • 2005 Summer Undergraduate Research and Creative Achievements Forum (MU)
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • Office of Undergraduate Research (MU)
    • Undergraduate Research and Creative Achievements Forum (MU)
    • 2005 Summer Undergraduate Research and Creative Achievements Forum (MU)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    In vitro evaluation of In-111-DOTA-anti-bcl-2-PNA-Tyr-3-octreotate in Chronic Lymphocytic Leukemia cells

    Hunter, Charles
    Jia, Fang
    Lewis, Michael R.
    View/Open
    [PDF] InVitroEvaluationIn-111-DOTA.pdf (15.43Kb)
    Date
    2005
    Contributor
    University of Missouri-Columbia. Office of Undergraduate Research
    Format
    Presentation
    Metadata
    [+] Show full item record
    Abstract
    The B-cell lymphoma/leukemia-2 (bcl-2) gene is overexpressed in many cancers. This gene increases cell survival by blocking apoptosis, or programmed cell death. The objective of this study was to evaluate radiolabeled peptide nucleic acid (PNA)-peptide conjugates targeting bcl-2 gene expression. DOTA-anti-bcl-2-PNA-Tyr-3-octreotate conjugate was labeled with In-111. Uptake, internalization, and efflux studies were performed in the human chronic lymphocytic leukemia (CLL) cell line Mec-1, which expresses both somatostatin receptors and bcl-2 mRNA. In the conjugate, octreotate is the somatostatin receptor ligand. Receptor and mRNA binding were also evaluated. Internalization of In-111-DOTA-anti-bcl-2-PNA-octreotate increased from 58.29% at 1min to 67.9% at 15min and reached 81% at 4h, whereas the internalized In-111-DOTA-Tyr-3-octreotate in Mec-1 cells started from 31.1% at 1min and gradually increased to 49.28% and 66.1% at 15min and 4h, respectively. Efflux analysis of Mec-1-In-111-DOTA-anti-bcl-2-PNA-Tyr-3-octreotate showed that 84.9% of radioactivity remained in the cells after 1min incubation and 60.0% of cell associated radioactivity was retained 4h later. Analysis of In-111-DOTA-Tyr-3-octreotate showed the cell associated radioactivity dropped from 85.1% at 1min to 69.1% at 4h.The western blot assay study showed a 51.0% bcl-2 protein synthesis inhibition by treatment with DOTA-anti-bcl-2-PNA-Tyr-3-octreotate. As a result, a peptide conjugate, which contains two molecular functions, was developed. These functions are receptor mediated tumor cell delivery and oncogene mRNA targeting. This agent has the potential to be used for detection of tumor bcl-2 expression by non-invasive molecular imaging.
    URI
    http://hdl.handle.net/10355/2142
    Part of
    2005 Summer Undergraduate Research and Creative Achievements Forum (MU)
    Collections
    • 2005 Summer Undergraduate Research and Creative Achievements Forum (MU)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems